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Why the renewed interest in triglyceride? 
With the disappointing results of the fibrate-statin combination trials (1) and the 
longstanding view that the positive association of plasma triglyceride with atherosclerotic 
cardiovascular disease (ASCVD) risk was irredeemably confounded mainly by its 
relationship to HDL (1,2), the concept that this lipid represented a reasonable target for 
CVD prevention slowly faded over the horizon. However, the requiem may have been 
premature - a number of current lines of evidence lead to the conclusion that triglyceride-
lowering may after all be an effective intervention strategy. First, the issue of confounding 
was addressed in a series of Mendelian randomisation studies that demonstrated that 
genetic variants altering plasma triglyceride levels led to differences in risk of ASCVD (3). 
In interpreting these studies, however, care must be taken not to assume that raised 
triglyceride directly causes atherosclerosis since this lipid is not found in abundance in 
plaque. Rather, perturbations in plasma triglyceride metabolism have consequences for 
cholesterol- transporting lipoproteins causing the accumulation of remnant lipoproteins 
(2,4), and changes in the structure and metabolism of LDL (1,2,5). Second, recent studies 
have shown the concentration of remnant lipoproteins to be associated with ASCVD 
outcomes independent of LDL cholesterol (LDLc) (2,4). The third line of evidence is the 
remarkably clear, positive result of the REDUCE-IT trial (6). This study in ASCVD subjects 
on background statin therapy with a plasma triglyceride in the range 1.52 to 5.63 mmol/l 
(135 to 499 mg/dl) reported a 25% lower risk in subjects allocated to ethyl eicosapentanoic 
acid at 4g/day versus placebo. 
 
Epidemiological studies consistently find that triglyceride exhibits a positive association 
with risk of a first ASCVD event (1,2). However, since statins are known to be able to 
reduce plasma triglyceride levels especially in individuals with hypertriglyceridemia (7), it 
has been debatable as to whether in well-treated populations with established ASCVD 
elevated plasma triglyceride retains a relationship to risk of a further event. This question 
has been addressed in a number of selected cohorts and in the more general population in 
the investigation of Lawler et al (8) reported in the current issue. Using a record linkage 
approach they explored in 196,717 subjects with prevalent ASCVD drawn from the 
CANHEART study, the relationship of plasma triglyceride to a composite CVD outcome 
measure. Increasing plasma triglyceride across the range <1.0 to >=4.0 mmol/l was 
associated with a 52% elevated risk of the primary endpoint. Where it could be ascertained 
(i.e. for subjects >=66 years old) most people (>95%) were on statin treatment and it is 
reasonable to assume (as the authors did) that this would be true of the whole cohort. The 
 
 
value of interrogating health records in this way lies in the fact that they reflect the ‘real 
world’ and on that basis it was predicted that in clinical practice about a quarter of ASCVD 
patients will have plasma triglyceride and (moderately well controlled) LDLc in the range 
used as entry criteria for the REDUCE-IT trial, and hence potentially would be eligible for 
triglyceride lowering therapy. This figure, however, is likely to be an upper estimate since it 
is based on a broad definition of hypertriglyceridemia. Adopting the more usual threshold 
of >2.3mmol/l (200mg/dl) (2,9) would identify substantially fewer candidates for this 
intervention.  In REDUCE-IT subjects were included initially using the full 135-499mg/dl 
range but the lower limit was adjusted to >=200mg/dl about halfway through recruitment. 
Hence, the mean plasma triglyceride (217mg/dl) was higher than seen in the CANHEART 
cohort (177mg/dl) (Table 4 in (8)). Whatever threshold is used, it is clear that a substantial 
proportion of ASCVD patients will exhibit on statin therapy elevated plasma triglyceride 
levels that are worth treating, possibly with ethyl eicosapentanoic acid (6) or with other 
high dose fish oil regimens (9), or with a PPAR agonist such as pemafibrate which is 
being investigated in a similar hypertriglyceridemic population in the ongoing PROMINENT 
study (10).  
 
What are the metabolic causes and consequences of hypertriglyceridemia? 
The range of triglyceride concentration used to define the cohort of subjects in REDUCE-
IT (6) and the study of Lawler et al (8) is wide, including those in the upper end of what 
clinical chemists term the normal range (up to 2.3 mmol/l) and those with classically 
defined moderate hypertriglyceridemia (2.3 to 5.0 mmol/l) (2,9). As triglyceride rises over 
this range the distribution of lipoprotein particles changes (Figure1). Large very low density 
lipoproteins (VLDL1) become the major triglyceride-rich species due to a combination of 
increased production from the liver (that in many is the result of high levels of liver fat and 
central insulin resistance (11) - about half of the subjects in the CANHEART cohort (8) and 
REDUCE-IT (6) were diabetic) and decreased lipolytic efficiency likely caused by high 
rates of apoC-III synthesis; apoCIII has long been recognised as an inhibitor of lipoprotein 
lipase (11). The presence of high levels of VLDL1 with a prolonged residence time in the 
circulation greatly increases the propensity to form remnants, so called because they are 
partially lipolysed triglyceride-rich lipoproteins that are no longer able to be efficiently 
delipidated. These particles are enriched in cholesterol, particularly cholesteryl esters, and 
are believed to be at least as atherogenic as LDL on a per particle basis (4,12). A further 
consequence of elevated levels of VLDL1 is the enhanced generation of small dense LDL 
that again is thought to be particularly atherogenic since it has reduced affinity for the LDL 
 
 
receptor and is more likely to bind to arterial wall proteoglycans (2,5). The 
hypertriglyceridemic patient is therefore in double jeopardy in terms of lipoprotein 
pathophysiology. Statins are able to induce accelerated clearance of VLDL remnants and 
LDL from the bloodstream and hence lower the incidence of ASCVD in 
hypertriglyceridemia (7) but there appears to be a residual risk that is amenable to 
targeted triglyceride reduction (1,2,9).   
 
Of course, the liver is not the only organ involved in triglyceride transport. The intestine 
when presented with dietary fat generates a wave of chylomicrons that enter the 
bloodstream and undergo rapid lipolysis using the same enzymatic pathway as VLDL1. In 
hypertriglyceridemia, chylomicron metabolism is compromised due possibly to high levels 
of apoCIII and the presence of abundant VLDL1 particles that compete for available 
lipoprotein lipase (Figure 1). The result is a greater peak triglyceride concentration during 
lipid absorption and the generation of high levels of chylomicron remnants (1,9). Since the 
intestine makes a short form of apoB (B48), whereas the liver makes full-length apoB100, 
it is possible to track the behavior of triglyceride-rich particles from these two tissue 
sources. In a recent study (13) we were able to show that apoB48-containing particles in 
hypertriglyceridemic subjects are released across the entire chylomicron-VLDL size range, 
persist for many hours, and accumulate to high levels thus adding to the circulating 
remnant particle population. It is worth noting that ‘remnant’ is primarily a metabolic term 
describing partially lipolysed, cholesteryl ester rich, slowly metabolized particles and as 
such these particles are a subset of the spectrum of triglyceride transporting lipoproteins 
found in the circulation (Figure 1). Thus, use of total VLDL cholesterol (8) is a surrogate 
measure for remnant cholesterol that is probably proportionate to the amount of remnants 
present but is not an accurate quantification of this subfraction. 
 
What happens when you lower triglyceride? 
Two therapeutic modalities are commonly used for the specific reduction of elevated 
plasma triglyceride levels – PPAR agonists/fibrates (1,2) and high doses of fish 
oil/omega-3 fatty acids (2,9). Their mechanisms of action have been well studied over 
many years; fibrates act mainly to increase VLDL clearance (1) whereas omega-3 fatty 
acids have been found to lower VLDL production in the liver (9,14). The impact of these 
drugs on the entirety of lipoprotein metabolism is a function of the basal plasma 
triglyceride level (1,5,9). Both classes of agents reduce the extent of chylomicronemia 
following a fat meal and hence the generation of apoB48-contining remnants, and by their 
 
 
effects on VLDL metabolism decrease the levels of VLDL (apoB100-containing) remnants. 
It is known that plasma triglyceride is the major factor controlling LDL particle size, so as 
the concentration of this lipid falls, LDL size will increase and the amount of small, dense 
LDL in the circulation will be reduced (1,4,9). The response in terms of LDLc concentration 
for most individuals will be little change (2,9), whereas those with initial triglyceride around 
5.0 mmol/l may experience a moderate increase in LDLc (5,9). Thus, as stated above, if 
the influence of dysregulation of plasma triglyceride on ASCVD risk is primarily through the 
impact on the apoB lipoprotein spectrum (Figure 1) then the benefits of lowering this lipid 
will be a function of the net effect on remnants and LDL. The importance of understanding 
the impact of triglyceride lowering strategies on the whole apoB-lipopotein spectrum is 
further emphasized in a recent investigation demonstrating that the ASCVD risk reduction 
associated with genetic variants that lower triglyceride is dependent on the associated 
reduction in apoB (15). Thus, relating change in triglyceride to change in risk may not be 
straightforward and in this context, it is of interest to note that in the REDUCE-IT trial there 
was no obvious relationship between basal triglyceride and reduction in risk (prompting 
discussion of potentially additional, non-lipoprotein mediated mechanisms in (6)).  
 
In conclusion, triglyceride lowering may have a new lease of life now that the focus has 
moved to subjects who are likely to receive the greatest benefit from this intervention. 
However, given the impact of raised triglyceride on the metabolism of the whole spectrum 
of apoB-containing lipoproteins, we should not expect interpretation of the relationship 
between lipid reduction and decreased ASCVD risk to be as straightforward as it has been 
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The impact of triglyceride levels on the apoB-containing lipoprotein spectrum is depicted 
schematically for those with an optimal level (TG 1.0 mmol/l) and those with moderate 
hypertriglyceridemia (TG 2.3-5.0mmol/l). The liver generates triglyceride-carrying 
lipoproteins associated with apoB100 that vary in size from large VLDL1 to smaller VLDL2. 
Lipoprotein lipase acts on VLDL to hydrolyse the core triglyceride and convert the particles 
to LDL as the terminal product of lipolysis. Subjects with optimal triglyceride levels make 
few remnants and the LDL formed is mostly large. Chylomicrons containing apoB48 as the 
main structural protein released from the intestine during lipid absorption are rapidly 
converted to smaller particles (remnants) that are cleared by the liver.  
Subjects with elevated plasma triglyceride levels overproduce VLDL1 due to high fat 
content in the liver and a failure of insulin to suppress VLDL1 synthesis (11). Lipolysis is 
also delayed due to the presence high levels of apoCIII, an inhibitor of lipoprotein lipase. 
Inefficient lipolysis leads to prolonged circulation times and increased cholesterol 
(cholesteryl ester) acquisition by VLDL that in turn favours formation of VLDL remnants. In 
those with high triglyceride, remodeling of LDL leads to the generation of high amounts of 
small, dense LDL (5). Chylomicron metabolism too is compromised with increased 
formation of apoB48-containing remnants. The relatively long-lived remnants and small 
LDL are available to bind to arterial wall proteoglycan and promote foam cell formation 
(4,12). 
 
  
  
 
 
Figure 1 
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